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Parkinson’s disease, typically thought of as a movement disorder, is increasingly recognized as causing cognitive impairment
and dementia. Eye movement abnormalities are also described, including impairment of rapid eye movements (saccades) and the
fixations interspersed between them. Such movements are under the influence of cortical and subcortical networks commonly
targeted by the neurodegeneration seen in Parkinson’s disease and, as such, may provide a marker for cognitive decline.
This study examined the error rates and visual exploration strategies of subjects with Parkinson’s disease, with and without
cognitive impairment, whilst performing a battery of visuo-cognitive tasks. Error rates were significantly higher in those
Parkinson’s disease groups with either mild cognitive impairment (P = 0.001) or dementia (P5 0.001), than in cognitively
normal subjects with Parkinson’s disease. When compared with cognitively normal subjects with Parkinson’s disease, explor-
ation strategy, as measured by a number of eye tracking variables, was least efficient in the dementia group but was also
affected in those subjects with Parkinson’s disease with mild cognitive impairment. When compared with control subjects
and cognitively normal subjects with Parkinson’s disease, saccade amplitudes were significantly reduced in the groups with
mild cognitive impairment or dementia. Fixation duration was longer in all Parkinson’s disease groups compared with
healthy control subjects but was longest for cognitively impaired Parkinson’s disease groups. The strongest predictor of average
fixation duration was disease severity. Analysing only data from the most complex task, with the highest error rates, both
cognitive impairment and disease severity contributed to a predictive model for fixation duration [F(2,76) = 12.52, P40.001],
but medication dose did not (r = 0.18, n = 78, P = 0.098, not significant). This study highlights the potential use of exploration
strategy measures as a marker of cognitive decline in Parkinson’s disease and reveals the efficiency by which fixations
and saccades are deployed in the build-up to a cognitive response, rather than merely focusing on the outcome itself.
The prolongation of fixation duration, present to a small but significant degree even in cognitively normal subjects with
Parkinson’s disease, suggests a disease-specific impact on the networks directing visual exploration, although the study also
highlights the multi-factorial nature of changes in exploration and the significant impact of cognitive decline on efficiency of
visual search.
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Introduction
To make sense of the visual environment, humans must direct the
fovea rapidly and accurately to appropriate parts of a given scene.
The rapid eye movements used to achieve this are known as sac-
cades and are interspersed with foveal fixations in a goal-directed
fashion (Henderson and Hollingworth, 1999). Spatially accurate
saccade generation is under the influence of frontal (Pierrot-
Deseilligny et al., 1995; Muri et al., 1996), supplementary and
parietal eye fields (Pierrot-Deseilligny et al., 1991; Muri et al.,
1996), as well as regions of the prefrontal and posterior parietal
cortex (Pierrot-Deseilligny et al., 1995, 2005). These cortical areas
project, via the superior colliculus, thalamus and basal ganglia, to
lower brainstem structures concerned with saccadic eye move-
ments (Hikosaka et al., 2000).
‘Runs’ of fixations and saccades are used to deliver visual infor-
mation, via the dorsal and ventral processing streams, to the
higher visual centres involved in visuoperceptual and visuospatial
processing (Ungerleider and Mishkin, 1982; Goodale and Milner,
1992). Neurodegeneration in Parkinson’s disease targets these re-
gions (Beyer et al., 2007; Pereira et al., 2009), as well as
fronto-parietal attentional and executive networks, leading to im-
pairments in visuospatial, visuoperceptual and executive function,
as well as attention and memory (Cormack et al., 2004;
Mosimann et al., 2004b; Muslimovic et al., 2005; Williams-Gray
et al., 2007). The co-localization of visual, cognitive and oculo-
motor functions provides an opportunity to use saccadic charac-
teristics to examine the cortical impact of Parkinson’s disease and
Parkinson’s disease dementia (Perneczky et al., 2011).
Patients with Parkinson’s disease display a number of eye move-
ment abnormalities; deficient smooth pursuit, restricted vergence
and reduced range of eye movements have all been described
(Corin et al., 1972; White et al., 1983; Rascol et al., 1989;
Repka et al., 1996; Bares et al., 2003). Evidence for disease-
specific disruption of saccadic programming and execution in
Parkinson’s disease is contradictory. Whereas some studies have
demonstrated increases in saccadic latency, reductions in ampli-
tude and increased error rates (Kennard and Lueck, 1989; Rascol
et al., 1989; Briand et al., 1999; MacAskill et al., 2002; Hood
et al., 2007; van Stockum et al., 2008), others have not replicated
these findings (Lueck et al., 1990; Vidailhet et al., 1994; Briand
et al., 1999, 2001; Vidailhet et al., 1999; Mosimann et al., 2005).
The properties of the stimulus used, medication effects and the
cognitive heterogeneity of study cohorts are important determin-
ants of saccadic metrics and may help explain some of the incon-
sistencies in the reported literature (Hodgson et al., 1999;
Mosimann et al., 2005; Michell et al., 2006; Hood et al., 2007;
Chambers and Prescott, 2010). For example, patients with neuro-
degenerative disorders characterized by cognitive impairment
(Alzheimer’s disease, Parkinson’s disease dementia and dementia
with Lewy bodies) show longer fixation durations, increased sac-
cadic latency and more saccadic errors than control subjects
(Lueck et al., 2000; Ogrocki et al., 2000; Mosimann et al.,
2005), suggesting cortical neurodegeneration can impair oculo-
motor function.
In addition to examining the absolute metrics of saccades and
fixations, the overall strategy used when interacting with complex
visual information can also be studied. For example, patients with
Alzheimer’s disease demonstrate impairments in text and clock
reading, with less focused visual exploration strategies correlating
with task error rates and dementia severity (Lueck et al., 2000;
Mosimann et al., 2004a). Facial emotion recognition is also im-
paired in Alzheimer’s disease, with fewer fixations on salient facial
regions and greater time spent in ‘off face’ areas (Ogrocki et al.,
2000). Parkinson’s disease also appears to alter gaze strategy.
Using a modified Tower of London task, Hodgson et al. (2002)
demonstrated less efficient distribution of fixations and saccades
and increased error rates in subjects with Parkinson’s disease com-
pared with control subjects. In addition to increased fixation dur-
ation whilst visually scanning commonly used visuocognitive tasks
(cube, overlapping figures, Rey-Osterrieth complex figure), cogni-
tively normal subjects with Parkinson’s disease made fewer sac-
cades, and of smaller amplitude, than control subjects. The area of
visual scanning was also smaller, with all these measures influ-
enced by the degree of image complexity (Matsumoto et al.,
2011). To date, there is no information available on the impact
of differing degrees of cognitive impairment on visual exploration
behaviour in Parkinson’s disease.
The aim of this study was to examine the impact of Parkinson’s
disease and Parkinson’s disease dementia on basic oculomotor met-
rics and eye tracking strategies. We hypothesized that, with impaired
cognition, exploration strategies would become less efficient. We
also hypothesized that basic oculomotor metrics, such as fixation
duration and saccade amplitude, would differ between control sub-
jects and subjects with Parkinson’s disease, but that the differences
would be greatest in those with cognitive impairment.
Materials and methods
Subjects
The study was approved by the National Health Service (NHS) Local
Research Ethics Committee, and all participants gave written informed
consent. Participants with Parkinson’s disease and Parkinson’s disease
dementia aged 449 years were consecutively recruited from the
Newcastle upon Tyne NHS Foundation Trust Movement Disorder ser-
vice. To supplement the number of patients with Parkinson’s disease
dementia in the study, additional subjects were approached from Par-
kinson’s disease nurse-specialist clinics. The healthy control cohort
comprised spouses/partners of study participants and was
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supplemented from a research database held at the Institute for
Ageing and Health, Newcastle University, UK. Total recruitment fig-
ures were as follows: Parkinson’s disease n = 64; Parkinson’s disease
dementia n = 26; control n = 32. All participants fulfilled UK Brain Bank
Criteria for a diagnosis of Parkinson’s disease (Hughes et al., 1992). All
Parkinson’s disease dementia participants met Movement Disorder
Society consensus criteria for dementia associated with Parkinson’s
disease (Emre et al., 2007).
Diagnostic procedures
Disease severity was assessed using the Unified Parkinson’s Disease
Rating Scale (UPDRS) part II and part III, part III reflecting the
degree of motor impairment (Fahn and Elton, 1987). Medications
were expressed as levodopa equivalent doses (LED) (Tomlinson
et al., 2010). Cognition was assessed using the Folstein Mini-Mental
State Examination (Folstein et al., 1975) and the Mattis Dementia
Rating Scale (DRS-2) (Brown et al., 1999). The DRS-2 consists of
five subscales, providing information on attention, initiation/persever-
ation, construction, conceptualization and memory. The scores of the
five subscales contribute to a total DRS-2 score, and normative data
allow adjustment for age and education [age- and education-adjusted
Mayo’s Older Americans Normative Studies subscale score (AEMSS)].
The construction subscale score of the DRS-2 may be insensitive to
subtle changes of visuoconstructional impairment in Parkinson’s dis-
ease; therefore, clock drawing, scored using the Shulman method
(Shulman, 2000), was included as part of the cognitive assessment.
To address the potential impact of cognitive heterogeneity on the
eye-tracking measures, we defined two non-demented Parkinson’s dis-
ease sub-groups: cognitively normal and those with mild cognitive
impairment (MCI). In the absence of published criteria for MCI in
Parkinson’s disease at the start of this study (Litvan et al., 2012),
we used both a global cognitive score (AEMSS) and domain subscale
scores (attention, initiation/perseveration, construction, conceptualiza-
tion, memory, Clock Drawing Test) to define MCI. An AEMSS score
51.5 standard deviations (SD) below the control group mean, or
52 domain subscale scores 51.5 SD below control group mean
values, was taken as evidence of MCI. This approach split the
Parkinson’s disease group into 37 subjects with normal cognition
(Parkinson’s disease-cognitively normal subjects) (58%) and 27 with
mild cognitive impairment (Parkinson’s disease-MCI subjects) (42%).
Assessment of visual exploration
Participants explored a range of visual stimuli, including an angle
matching task, a clock task (regular and inverted clocks), a shape
position task and an overlapping figures task, as part of an eye track-
ing battery (Fig. 1).
Overlapping figures, first described by Poppelreuter (1917) and
Ghent (1956) and formalized by De Renzi et al. (1969), have been
used in previous studies of Parkinson’s disease dementia and dementia
with Lewy bodies (De Renzi et al., 1969; Mori et al., 2000; Mosimann
et al., 2004b) to provide information on impairment of object-form
perception. In our experiment, participants were required to study a
central composite image and choose which one of four individual
comparators presented underneath appeared centrally.
Clock reading is an over-learned perceptual task that is impaired
both in Alzheimer’s disease, dementia with Lewy bodies and patients
with parietal lobe lesions (Schmidtke and Olbrich, 2007). Visual
exploration of clock faces is impaired in Alzheimer’s disease, with pa-
tients making fewer fixations at the ends of the clock hands and taking
longer to explore the clock face (Mosimann et al., 2004a). Although
clock drawing is frequently impaired in Parkinson’s disease dementia
(Cahn-Weiner et al., 2003), clock reading has not been studied in
Parkinson’s disease and Parkinson’s disease dementia. For this
reason, we included a clock task, requiring participants to perform
both clock reading and clock matching. An inverted clock task was
also included in the test battery, introducing a greater spatial compo-
nent to the clock task, by requiring participants to mentally rotate the
comparators by 180 before giving their response (Amick et al., 2006).
Impairment in the judgement of line orientation is impaired in
Parkinson’s disease and Parkinson’s disease dementia (Montse et al.,
2001; Mosimann et al., 2004b). Owing to the screen layout constraints,
we modified Benton’s original task, requiring participants to match a
centrally presented angle to one of four comparator angles beneath.
Finally, we included a shape position in the battery. This task incorpo-
rated elements of the position discrimination task of Warrington and
James (1988) and the spatial location task of MacQuarrie (1953), pre-
viously found to be impaired in Parkinson’s disease dementia and de-
mentia with Lewy bodies (Mori et al., 2000; Mosimann et al., 2004b).
Stimuli were presented on a 20-inch TFT computer monitor, and eye
movements were recorded with an EyeLink 1000 remote eye tracker
(EyeLink, SR Research Ltd). Participants were positioned 80 cm from
the stimulus monitor, wore normal refractive correction and were able
to resolve the stimuli presented during a practice block, in the training
phase of the experiment. Viewing was binocular, but recordings were
made from one or other eye. A chin rest and forehead bar maintained
the participant’s head position and distance from the computer moni-
tor. Measurements of eye movements were conducted in a dimly lit
room, and online viewing of data collection was undertaken behind a
blackout curtain.
The eye tracker was calibrated for each participant before each ex-
periment. Calibration consisted of having the participant fixate on nine
calibration points (three points each across the top, middle and bottom
of the screen), one at a time. Stimuli were presented in blocks:
angle-clock-inverted clock; shape position; overlapping figure, in a
pseudorandom fashion. Each block began with a previously viewed
practice image, followed by 16 trial images, presented in one of six
randomized orders. A total of 80 images were viewed by each par-
ticipant, and the battery took 10–15 min to complete. Participants
were encouraged to take a break if required. Screen layout was iden-
tical for each stimulus, with a central stimulus and four comparators
arrayed beneath. All comparators appeared equally for each category,
to ensure no bias emerged for any particular choice option.
Participants gave a verbal response (‘1’,’2’,’3’ or ‘4’), at which point
the investigator (N.A.) activated a key press, and the stimulus moved
on to a central fixation point, before the next stimulus presentation.
The EyeLink 1000 system incorporates a unique on-line parsing
system that analyses eye position data into meaningful events and
states (saccades, fixations and blinks). The average duration of fix-
ations (ms) and saccade amplitudes (degrees) were analysed. Interest
areas, such as the central stimulus, four comparator stimuli and
correct/incorrect interest areas were defined for each visual stimulus
(Fig. 2). Analysis of the distribution of fixations in correct and incorrect
interest areas, the first interest areas explored and the number of times
a given interest areas is revisited during exploration (run count) reveals
the strategy used by participants to solve the visual task presented to
them. We chose three measures to define the efficiency of the visual
exploration strategy: time to first fixation in the correct interest area,
run count into the central stimulus and run count ratio.
The run count ratio is generated from the mean run count into the
three incorrect interest areas, divided by the run count into the correct
interest area. Low run count ratios reflect a strategy where the correct
interest areas are explored in preference to incorrect regions. High run
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count ratios suggest either a less efficient strategy, where incorrect
interest areas are revisited repeatedly, or a cautious approach, aimed
at minimizing errors. Time to first fixation in the correct interest area
was chosen, as this measure has previously been demonstrated to
provide information on efficiency of visual exploration during clock
reading in patients with Alzheimer’s disease (Mosimann et al.,
2004a). Run count and run count ratio are novel approaches to quan-
tifying gaze distribution, although gaze distribution itself has previously
been shown to be impaired in Parkinson’s disease during a ‘one touch’
Tower of London task (Hodgson et al., 2002).
Not all subjects contributed to the final eye tracking data set, for a
variety of reasons outlined in the flow chart (Fig. 3). Reasons for data loss
included withdrawal from the study, inability to tolerate the test or failure
of the eye-tracking equipment. The recruitment figures for this part of
the study were therefore as follows: control subjects n = 29, cognitively
normal Parkinson’s disease subjects n = 35, Parkinson’s disease-MCI sub-
jects n = 22 and Parkinson’s disease dementia n = 22. In addition, a pro-
portion of participants completed only part of the eye-tracking battery,
due to poor comprehension, fatigue, drowsiness and so forth. As ex-
pected, the group most affected by data loss was the Parkinson’s disease
dementia cohort. When comparison was made between the demographic
features of those subjects with Parkinson’s disease dementia completing
every task in the battery (n = 16) and those failing to do so (n = 10),
there were no differences in age (Wilcoxon rank sum; z = 0.40,
P = 0.692, not significant), education (Wilcoxon rank sum; z = 0.08,
P = 0.934, ns), UPDRS III (Wilcoxon rank sum; z = 0.77, P = 0.444, not
Figure 1 Tests used in the eye-tracking battery. Note the standardized screen layout, with a central stimulus and four comparator stimuli
underneath. Tasks within the battery included an angle matching task, clock and inverted clock matching task, shape position task and
overlapping figures task.
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significant) or global cognition (AEMSS: Wilcoxon rank sum; z = 0.64,
P = 0.507, not significant). Subjects failing to complete the eye tracking
battery did, however, have a significantly longer dementia duration
(Parkinson’s disease duration: Wilcoxon rank sum; z = 2.27, P = 0.023;
dementia duration: Wilcoxon rank sum; z = 2.68, P = 0.007).
Statistics
Data were analysed using the JMP 8 statistical package (SAS Institute
Inc.). The distribution of data was examined for normality (Shapiro–
Wilk test). Means and standard deviations were calculated. Normally
distributed data were analysed with parametric tests (independent
sample t-tests, ANOVA) and non-normally distributed data with
non-parametric tests (Wilcoxon rank sums, Kruskal–Wallis). Pearson
chi-square test was used for comparison of frequencies, and Fisher’s
exact test used when expected frequency in either group was 55. All
reported P-values are two-tailed for parametric tests. Wilcoxon rank
sum test results are presented using normal approximation, and a P-
value of 50.05 was considered significant.
Planned group comparisons for the eye-tracking analysis were as
follows: (i) control versus cognitively normal Parkinson’s disease sub-
jects; (ii) cognitively normal Parkinson’s disease subjects versus
Parkinson’s disease-MCI subjects; (iii) cognitively normal Parkinson’s
disease subjects versus Parkinson’s disease dementia subjects; and (iv)
Parkinson’s disease-MCI subjects versus Parkinson’s disease dementia
subjects. The relationship between global cognition (AEMSS), disease
severity (UPDRS III), LED and average fixation duration was investi-
gated using Pearson product-moment correlation coefficient and step-
wise linear regression (standard least squares approach with backward
elimination). The same analysis was performed using just the fixation
duration for the overlapping figures task to explore the association be-
tween task complexity, cognition, motor status and fixation duration.
This was selected as the dependent variable because the overlapping
figures task had the highest error rates and greatest task complexity.
Figure 2 Example of fixation/saccade map for a single study participant. Blue circles represent each fixation, with the size of each circle
reflecting the individual fixation duration. Yellow arrows represent each saccade. Interest area analysis provides insight into the visual
exploration strategy used for each image viewed. IA = interest area; RC = run count.
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Results
Demographic characteristics
Demographic and cognitive features are shown in Table 1. All four
groups were well matched for age and education. Estimated
dementia duration was 1.7 years (range 0–3 years, where 0 rep-
resents a new diagnosis of dementia at study entry). Cognitively
normal Parkinson’s disease subjects and control subjects were well
matched for global and subscale cognition. Parkinson’s
disease-MCI subjects scored lower than cognitively normal
Parkinson’s disease subjects and control subjects on all cognitive
Figure 3 Flow chart for the eye-tracking study. Note the smaller number taking part in the eye tracking experiment owing to withdrawal,
recording failure or problems tolerating the procedure. In addition, several of the eye-tracking cohorts failed to complete all five tasks in
the battery. CNL = cognitively normal.
744 | Brain 2013: 136; 739–750 N. K. Archibald et al.
subscale scores of the DRS-2, apart from the construction scale
previously noted to discriminate poorly between cognitively
normal and cognitively impaired individuals.
Eye-tracking battery performance
Task performance
Error rates, expressed as a percentage of the total trials, illustrate
the types of visual task found most challenging by the study sub-
jects (Table 2). For all groups, fewest errors were made on the
clock task, followed by the angle, shape, inverted clock and over-
lapping figures tasks. There was no difference between control
subjects and cognitively normal Parkinson’s disease subjects in
the total number of errors made on the battery, or in error rate
percentages on the individual task types. There were, however,
significant differences in performance between the three
Parkinson’s disease groups. Compared with the cognitively
normal Parkinson’s disease group, error rate percentages on
angle and overlapping figures tasks were significantly higher in
the Parkinson’s disease-MCI group, and there was a trend towards
significance for the inverted clock task. Comparison of error rates
between cognitively normal Parkinson’s disease and Parkinson’s
disease dementia groups reached significance for all five tasks.
Parkinson’s disease-MCI subjects made significantly fewer errors
than those with Parkinson’s disease dementia, with the exception
of performance on the inverted clock task, where Parkinson’s
disease-MCI performance closely resembled that of the dementia
group.
Saccade amplitude
Saccade amplitude was largest for the control group, with a gen-
eral trend towards progressively lower saccadic amplitudes across
the three disease groups (cognitively normal Parkinson’s disease 4
Parkinson’s disease-MCI 4 Parkinson’s disease dementia)
(Table 3). There was a significant difference in amplitudes be-
tween cognitively normal subjects with Parkinson’s disease and
those with both MCI and dementia. Comparisons between
Parkinson’s disease-MCI and Parkinson’s disease dementia
groups did not reach significance. Of note, although cognitively
normal Parkinson’s disease subjects had reduced saccadic ampli-
tudes compared with control subjects, this comparison also failed
to reach significance (P = 0.178, not significant).
Fixation duration
The average duration of fixations was shorter in control subjects
than cognitively normal Parkinson’s disease subjects (Table 3). A
similar pattern was seen when comparing cognitively normal
Parkinson’s disease subjects with Parkinson’s disease-MCI subjects.
The trend to prolonged fixation duration was replicated when
comparing Parkinson’s disease-MCI subjects with subjects with














n = 35 n = 22 n = 22
Age (years) 72.3 (7.8) 69.4 (9.0) 70.8 (7.1) 72.3 (6.0) 0.409a (ns)
Education (years) 11.6 (2.7) 12.3 (3.1) 12.0 (3.4) 11.2 (3.0) 0.361b (ns)
Gender (% male) 48 60 77 86 0.451c,d (ns), 0.025e (ns), 0.042f, 0.698g (ns)
Parkinson’s disease duration (years) n/a 7.6 (5.6) 8.8 (5.4) 11.6 (6.1) 0.426e,h (ns), 0.015f, 0.118g (ns)
Estimated dementia duration (years) n/a n/a n/a 1.7 (0.9)
UPDRS II n/a 11.9 (6.4) 14.9 (5.4) 28.8 (5.8) 0.099e,i (ns), 50.001f,g
UPDRS III n/a 21.3 (10.5) 25.6 (8.8) 35.4 (14.7) 0.187e,i (ns), 0.001f, 0.023g
LED n/a 579 (406) 774 (479) 917 (450) 0.105e,h (ns), 0.005f, 0.312g (ns)
Global cognition
Mini-Mental State Examination 29.6 (0.8) 29.5 (0.7) 28.3 (1.6) 24.5 (2.7) 0.219d,i (ns), 0.003e 50.001f,g
AEMSS (DRS) 12.8 (2.9) 12.4 (2.1) 7.6 (2.5) 3.9 (1.7) 0.487d,i (ns), 50.001e,f,g
Cognitive subscale scores (DRS)
Attention 12.2 (1.3) 12.1 (1.2) 10.9 (1.9) 9.9 (2.6) 0.813d,i (ns), 0.012e, 50.001f, 0.231g (ns)
Initiation/perseveration 11.0 (1.4) 11.0 (1.3) 6.8 (2.5) 4.1 (2.0) 0.785d,i (ns), 50.001e,f,g
construction 10.0 (0.0) 10.0 (0.0) 9.7 (0.9) 8.7 (2.3) n/ad,i, 0.072e, 0.001f, 0.097g (ns)
Clock Drawing Test (Shulman) 4.9 (0.3) 4.7 (0.4) 4.2 (0.9) 2.9 (1.5) 0.050d,i (ns), 0.020e, 50.001f, 0.001g
Conceptualization 11.5 (1.5) 10.9 (1.6) 9.2 (2.8) 8.1 (3.2) 0.149d,i (ns), 0.021e, 50.001f, 0.267g (ns)
Memory 10.0 (3.2) 10.6 (1.9) 8.1 (3.1) 4.6 (2.5) 0.734d,i (ns), 0.002e, 50.001f,g
Values expressed as means (SD) (unless otherwise stated).
a ANOVA test.
b Kruskal-Wallis test.
c Pearson 2 Fisher’s exact test where groups frequency 55.
d Control subjects versus Parkinson’s disease-CNL subjects.
e Cognitively normal Parkinson’s disease subjects versus Parkinson’s disease-MCI subjects.
f Cognitively normal Parkinson’s disease subjects versus Parkinson’s disease dementia subjects.
g Parkinson’s disease-MCI subjects versus Parkinson’s disease dementia subjects.
h t-test.
i Wilcoxon rank sum test.
CNL = cognitively normal; ns = non-significant.
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Parkinson’s disease dementia, although the comparison just failed
to reach significance (P = 0.052). The comparison between cogni-
tively normal Parkinson’s disease subjects and those with dementia
was the most striking, with fixations in the Parkinson’s disease
dementia group lasting 40 ms longer than the cognitively
normal Parkinson’s disease group.
There was a significant negative correlation between AEMSS
and average fixation duration (r = 0.31, n = 68, P = 0.011), a
strong positive correlation between UPDRS III and fixation dur-
ation (r = 0.50, n = 68, P5 0.001) and a significant negative cor-
relation between AEMSS and UPDRS III (r = 0.37, n = 68,
P = 0.001). There was a weak, and non-significant, correlation
between fixation duration and LED (r = 0.17, n = 68, P = 0.164,
not significant). Multiple regression was used to assess the contri-
bution that global cognition (AEMSS) and motor severity (UPDRS
III) made to duration of fixation. A model containing both meas-
ures was significant [F(2,68) = 12.50, P40.001], predicting 28%
of the variance in fixation duration. As suggested by the correl-
ation analysis, UPDRS III positively correlated with fixation dur-
ation (b = 0.45, P40.001) and contributed most to the model,
whereas AEMSS negatively correlated with fixation duration and
made a weaker, non-significant contribution to the overall predict-
ive value of the model (b = 0.16, P = 0.150, not significant). In
contrast, re-running the model for the overlapping figures task
yielded a slightly stronger model [F(2,76) = 12.52, P4 0.001],
predicting 34% of the variance in fixation duration. UPDRS III



















Total 6.20 (0.54) 5.94 (0.52) 5.54 (0.79) 5.28 (0.69) 0.178a,b (ns), 0.027c, 50.001d, 0.174e (ns)
Fixation duration (ms)
Total 185 (22) 203 (29) 222 (32) 241 (41) 0.022a,b, 0.029c, 50.001d, 0.052e (ns)
Time to first fixation in
correct interest area (ms)
Total 1749 (271) 1920 (335) 2299 (674) 2811 (775) 0.187a,b (ns), 0.008c, 50.001d, 0.003e
Run count (central)
Total 3.02 (0.40) 2.86 (0.36) 3.15 (0.44) 3.48 (0.64) 0.313a,b (ns), 0.020c, 50.001d,0.026e
Run count ratio
Total 0.46 (0.08) 0.45 (0.07) 0.51 (0.07) 0.57 (0.11) 0.752a,b (ns), 0.010c, 50.001d, 0.036e
Values expressed as means (SD).
a Statistical tests: t-test.
b Control subjects versus cognitively normal Parkinson’s disease subjects.
c Cognitively normal Parkinson’s disease subjects versus Parkinson’s disease-MCI subjects.
d Cognitively normal Parkinson’s disease subjects versus Parkinson’s disease dementia subjects.
e Parkinson’s disease-MCI subjects versus Parkinson’s disease dementia subjects.
CNL = cognitively normal; ns = non-significant.
Table 2 Perception errors across the study groups












n = 35 n = 22 n = 22
Total 2.8 (2.9) 2.3 (2.0) 6.9 (6.1) 14.5 (12.0) 0.838a,b (ns), 0.001c, 50.001d, 0.015e
Angle 1.7 (2.8) 1.6 (3.1) 4.9 (6.0) 13.1 (10.0) 0.727a,b (ns), 0.012c, 50.001d, 0.002e
Clock 0.2 (1.1) 0.5 (2.3) 1.4 (3.2) 5.3 (7.4) 0.672a,b (ns), 0.324c (ns), 50.001d, 0.006e
Inverted clock 3.8 (6.3) 3.4 (5.3) 12.2 (19.8) 19.5 (26.0) 0.747a,b (ns), 0.079c (ns), 0.002d, 0.277e (ns)
Shape 2.7 (6.3) 3.6 (5.3) 3.5 (3.7) 16.4 (16.9) 0.265a,b (ns), 0.602c (ns), 0.002d, 0.010e
Overlap 5.0 (6.1) 3.3 (4.4) 10.9 (11.8) 20.2 (16.9) 0.275a,b (ns), 0.003c, 50.001d, 0.037e
Values expressed as means (SD).
a Statistical tests: Wilcoxon rank sum test.
b Control subjects versus cognitively normal Parkinson’s disease subjects.
c Cognitively normal Parkinson’s disease subjects versus Parkinson’s disease-MCI subjects.
d Cognitively normal Parkinson’s disease subjects versus Parkinson’s disease dementia subjects.
e PD-Parkinson’s disease versus Parkinson’s disease dementia.
CNL = cognitively normal; ns = non-significant.
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remained the strongest contributor (b = 0.44, P40.001), and
AEMSS made a weaker, but significant, contribution to the overall
predictive value of the model (b = 0.27, P = 0.013).
Exploration strategy by diagnostic group
In general, control subjects were first to fixate the correct interest
areas, with cognitively normal Parkinson’s disease, Parkinson’s
disease-MCI and Parkinson’s disease dementia subjects taking pro-
gressively longer (Table 3). Although there was no significant dif-
ference in total time to first correct fixation between cognitively
normal Parkinson’s disease and control subjects, comparisons be-
tween the three Parkinson’s disease groups were significant. The
most striking difference in the Parkinson’s disease group compari-
son was between cognitively normal subjects and those with de-
mentia. Cognitively normal Parkinson’s disease central run count
strategy matched that of control subjects. The total central run
count strategy was significantly different between cognitively
normal Parkinson’s disease, Parkinson’s disease-MCI and
Parkinson’s disease dementia subjects. As with time to first correct
fixation, the strategic performance of subjects with Parkinson’s
disease dementia was most impaired. The total run count ratio
was similar for control and cognitively normal Parkinson’s disease
groups. In line with the other strategic measures, total run count
ratio increased significantly across the three Parkinson’s disease
groups.
Discussion
To the best of our knowledge, this is the first study to report on
visual cognition and visual exploration strategy in Parkinson’s dis-
ease with predefined and differing levels of cognitive impairment.
We have demonstrated significant differences in visual exploration
strategies between cognitive sub-groups of Parkinson’s disease
and shown the potential of visual exploration analysis in providing
non-verbal and objective measures of cognitive dysfunction in
Parkinson’s disease.
Our results highlight the cognitive heterogeneity present in a
cross-sectional cohort of patients with Parkinson’s disease and
Parkinson’s disease dementia. This is particularly true of
non-demented Parkinson’s disease cohorts, where a significant
proportion of subjects are likely to have cognitive impairment
(Foltynie et al., 2004). In particular, non-demented patients with
Parkinson’s disease are reported to have impairments in executive
function, memory, visuospatial and visuoperceptual abilities
(Mosimann et al., 2004b; Muslimovic et al., 2005; Uc et al.,
2005; Williams-Gray et al., 2007). In the absence of published
criteria at the start of the study, we relied on global and subscale
cognitive scores to identify those subjects with Parkinson’s disease
who, although not fulfilling diagnostic criteria for Parkinson’s dis-
ease dementia, clearly did not score in the normal range—a group
we defined as ‘MCI’. Although we did not perform the detailed
neuropsychological assessments used in some previous studies of
Parkinson’s disease-MCI subjects (Janvin et al., 2006; Caviness
et al., 2007; Petersen et al., 2009), analyses suggest that our
approach did generate a group with a cognitive phenotype very
different from the cognitively normal Parkinson’s disease group.
The percentage of defined as Parkinson’s disease-MCI was also
comparable with previous studies (Litvan et al., 2011), suggesting
that our approach has external validity.
With respect to performance on the eye-tracking battery, we
found very similar low error rates for both control and cognitively
normal Parkinson’s disease groups, and no evidence to suggest a
specific visuospatial or visuoperceptual deficit in subjects with
Parkinson’s disease with normal cognition. This contrasts with
the performance of subjects with Parkinson’s disease-MCI, who
demonstrated significant differences in memory, attentional and
frontal-executive abilities, as well as higher error rates on visuo-
spatial and visuoperceptual tasks. The extent of these deficits was
intermediate between the cognitively normal Parkinson’s disease
group, who performed as control subjects, and the Parkinson’s
disease dementia group, with the highest error rates.
Interestingly, clock reading and matching was not markedly im-
paired in the Parkinson’s disease dementia group (5% error rate),
perhaps reflecting the over-learned nature of the task.
In line with our first hypothesis, exploration strategy, as defined
by time to first correct fixation, central run count and run count
ratio, was identical for control subjects and cognitively normal
subjects with Parkinson’s disease. Subjects in the cognitively
normal Parkinson’s disease, Parkinson’s disease-MCI and
Parkinson’s disease dementia groups differed in all exploration ef-
ficiency strategy measures. As expected, the most striking differ-
ences were between the cognitively normal Parkinson’s disease
subjects and those with dementia. This clear separation of
groups based on novel measures of exploration strategy provides,
for the first time, a measure not only of the outcome of a cogni-
tive task (correct versus incorrect) but also of how efficiently fix-
ations and saccades are deployed in the build-up to a cognitive
response.
In keeping with our second hypothesis, we noted small, but
significant, differences in fixation duration across the study
cohort. Despite being well matched for error rates, subjects in
the cognitively normal Parkinson’s disease group made consist-
ently longer fixations than control subjects, in the magnitude of
18 ms. This prolongation of fixation duration was most marked in
subjects with Parkinson’s disease with dementia; those with MCI
represented an intermediate group.
Although saccade amplitudes were lower in the cognitively
normal Parkinson’s disease group than control subjects, the com-
parison did not reach significance. Rather, it was those subjects
with Parkinson’s disease with MCI or dementia that demonstrated
significant reductions in saccade amplitude. This is in contrast to a
recent study of visual scanning in Parkinson’s disease, where dif-
ferences in fixation duration between patients with Parkinson’s
disease and control subjects were of much greater magnitude
than in our study, 40–150 ms (depending on task complexity),
and Parkinson’s disease saccadic amplitudes were significantly
lower (Matsumoto et al., 2011).
These differences may be explained, in part, by the differing
nature of the tasks; in our study, subjects matched comparator
images against a central stimulus—a standardized screen layout
across all five tasks; Matsumoto et al. (2011) required subjects
to memorize a variety of visual images of varying complexity.
Intuitively, one would predict that the latter task would generate
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longer fixations than those seen in our study. With respect to
saccade amplitude in control subjects and cognitively normal
Parkinson’s disease subjects, it may be that the observed trend
in our study would have reached significance had a greater
number of iterations been performed. Given the more striking
differences in saccade amplitude observed in those subjects with
Parkinson’s disease with MCI and dementia, it is possible that
unrecognized cognitive heterogeneity in previous study cohorts
might have influenced saccadic measures.
One potential explanation for the prolonged fixation duration is
a Parkinson’s disease-specific oculomotor deficit, resulting from
disruption of subcortical and cortical saccadic eye movement con-
trol, leading to a delay between the intention to make a voluntary
saccade and its actual initiation. An alternative explanation would
be that impairment of visual cognition, executive function or at-
tention, too subtle to be picked up by cognitive screening, is
influencing the characteristics of the fixations, even in cognitively
normal subjects with Parkinson’s disease. Such impairment, requir-
ing subjects to spend longer in each location to extract adequate
visual information, could result in small changes in fixation dur-
ation without necessarily causing higher error rates on the visual
battery itself.
Parkinson’s disease severity, reflected by UPDRS III score, was
the most important predictor of fixation duration in our regression
model, both for average fixation duration across all five tasks and
when the model was applied only to the overlapping figures
task—the most demanding of the conditions and the one with
the highest error rates. In addition, global cognition, as assessed
by the AEMSS score, made a significant contribution to the pre-
dictive model when task complexity was greatest. In contrast, total
LED did not contribute to either model.
As cognition declines and motor impairment worsens, fixation
duration becomes significantly longer. The longer fixation duration
is therefore a potential reflection not just of subcortical oculomotor
deficits but may also serve to highlight the involvement of
fronto-parietal eye fields and/or dorsal and ventral streams in
the neurodegenerative process in Parkinson’s disease. In support
of this argument, Perneczky et al. (2011) demonstrated negative
correlations between frontal executive function, grey matter
volume in the frontal and parietal eye fields and the latency of
visually evoked saccades.
Data on the metrics of fixations and saccades during ‘naturalis-
tic’ scene viewing in Parkinson’s disease are conflicting. There are
reports of prolonged fixations during reading and scanning of
visuocognitive tasks (Gottlob et al., 2004; Matsumoto et al.,
2011), but in a study of visual exploration duration the Tower
of London task, Hodgson et al. (2002) showed that, despite stra-
tegic differences between subjects with Parkinson’s disease and
control subjects, fixation durations were identical. Fixation dur-
ation during facial emotion viewing is influenced by executive
function in Parkinson’s disease (Clark et al., 2010), and the
impact of cognitive impairment on fixation characteristics is there-
fore an important factor in interpreting our results. It has been
argued that saccadic measurements (latency, amplitude, velocity)
may act as a surrogate neurophysiological biomarker for disease
progression in clinical trials of Parkinson’s disease, although the
interaction between medication effects, and the influence of
both cortical and subcortical structures, makes such an approach
potentially challenging (Barker and Michell, 2009).
There are limitations to our study in terms of recruitment and
sample size. We effectively excluded patients aged 550 years, to
allow adequate age matching of the study groups. However, as
the average age of the Parkinson’s disease population in clinic and
community-based studies is 70–72 years (Lo et al., 2009; Newman
et al., 2009), we feel our results are likely to have considerable
external validity. We employed consecutive recruitment for the
Parkinson’s disease group to minimize potential bias, but the de-
mentia cohort was a convenience sample. Our sample sizes were
relatively small compared with other studies of cognition in
Parkinson’s disease, and withdrawals from the study, technical
issues and an inability to complete the protocol resulted in a
degree of data loss, most evident in the Parkinson’s disease de-
mentia group. However, this is one of the largest eye-tracking
studies of Parkinson’s disease to date, the first to include patients
with dementia, and the first to explore the influence of differing
degrees of cognitive impairment on visual exploration.
Concerns over deteriorating performance and drop-outs asso-
ciated with a longer assessment battery dictated that we use a
relatively small number of images within each task category.
Refinement of the battery to those tasks most likely to discriminate
cognitive sub-groups would allow a greater number of iterations to
be run. A much more detailed cognitive assessment battery would
be required to better define the interaction between attention, ex-
ecutive function, working memory and the perceptual and spatial
abilities required to efficiently dissect out these ‘visual’ tasks.
Further studies are warranted, perhaps incorporating assessment
of reflexive and voluntary saccades, in addition to more naturalistic
scene/object viewing, to provide a more complete picture of the
influence of Parkinson’s disease on eye movement control.
Using eye tracking to measure visual search strategies during
task performance, combined with more basic measures of oculo-
motor control such as average fixation duration and saccade la-
tency, provides an alternative means of assessing and quantifying
cognitive impairment in Parkinson’s disease and may even act as a
surrogate biomarker for those at risk of cognitive impairment. If
replicated in longitudinal studies, visual exploration measures and
saccadic metrics may ultimately provide a new way of monitoring
response to novel disease-modifying agents and cognitive enhan-
cers, as and when they become available.
The functional implications of disordered visual exploration are
unknown, but, given that cortical saccade programming and inte-
gration of visuospatial input with motoric output are performed
in contiguous cortical regions, disruption of efficient visual explor-
ation strategies may contribute to motor complications such as
visually induced gait freezing, difficulty turning and falls.
Turning, for example, involves a complex integration of eye and
head movements, in conjunction with trunk rotation and stepping
(Hollands et al., 2004), and the risk of falling in older adults is
associated with delays between horizontal saccade initiation and
the beginning of foot lift (Greany et al., 2008). Additionally, freez-
ing of gait is often precipitated by turning and can lead to lateral
falls and injury (Spildooren et al., 2010). Subtle perturbations in
the turning sequence can be demonstrated in early Parkinson’s
disease; eye movements contribute more to gaze shift than in
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healthy control subjects (Anastasopoulos et al., 2011), and, at
least in a static environment, saccade performance is predictive
of ‘on the spot’ turn performance (Lohnes and Earhart, 2011).
Under more complex, naturalistic conditions such as walking and
turning under cognitive distraction, subjects with Parkinson’s dis-
ease make fewer, early ‘preparatory’ saccades before turning, with
these measures associated with poorer cognition (Galna et al.,
2012).
Given that the most striking changes in saccade amplitude, fix-
ation duration and exploration efficiency are seen in those subjects
with cognitive impairment, and that postural instability and falls
are strongly associated with cognitive decline (Yarnall et al.,
2011), our results suggest that oculomotor characteristics have
the potential to predict those at risk of motor complications. A
longitudinal study, combining detailed ‘static’ assessments of visual
exploration, with a more ‘dynamic’ approach, using portable eye
tracking devices during walking, would allow this hypothesis to be
tested. A better understanding of the distribution of gaze during
navigation may, ultimately, facilitate the tailoring of visual cueing
strategies to help overcome freezing when turning.
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